Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118792 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 764
- Enrollment target
NCT02118792: Completed Phase 3 study, sponsored by Pfizer.
NCT02118792 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 764 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02118792, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 764 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
Primary Outcome
ISGA assessed the severity of AD (except scalp) on a 5-point scale ranged from 0 (clear) to 4 (maximum severe), where higher scores indicate higher degree of AD. Grades for classification of severity: 0= clear (minor residual hypo/hyper pigmentation, no erythema or induration or papulation, no oozing or crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration or papulation and no oozing or crusting), 2= mild (faint pink erythema with mild induration or papulation
Interventions
- DRUG AN2728 Topical Ointment, 2%
- DRUG Matching vehicle control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 764 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT02118792 record still lists
NCT02118792 is an interventional study that assigns participants to a tested intervention. The registered 764 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which AN2728 Topical Ointment, 2% is the first listed.
NCT02118792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02118792 about?
NCT02118792 is a clinical study titled "Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis". The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
What is the current status of trial NCT02118792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 764 participants. The study started on 2014-03. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02118792?
The interventions under investigation include: AN2728 Topical Ointment, 2% (DRUG), Matching vehicle control (DRUG).
Who is sponsoring clinical trial NCT02118792?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02118792's enrollment target sits among peer trials
764 449th of 2000 higher than 1,552 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- NCT07195591 · 766 participants · Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia